UP!
Array BioPharma is a clinical stage publicly traded pharmaceutical company (NASDAQ:ARRY) that is included in the NASDAQ Biotechnology Index.
| Period | Date | Adjusted Actuals EPS | GAAP EPS |
|---|---|---|---|
| Q3 2021 | 2022-11-09 | Future report Set alerts | |
| Q2 2021 | 2022-08-09 | 0.09 | 0.09 |
| Q1 2021 | 2022-05-10 | 0.00 | 0.00 |
| Q4 2020 | 2022-04-05 | -0.06 | -0.06 |
| Q3 2020 | 2021-11-11 | -0.07 | -0.07 |
| Q2 2020 | 2021-08-11 | 0.07 | 0.07 |
| Q1 2020 | 2021-05-11 | 0.19 | 0.19 |
| Q4 2019 | 2021-03-09 | 0.08 | 0.08 |
| Q3 2019 | 2019-05-07 | -0.17 | -0.17 |
| Q2 2019 | 2019-02-05 | -0.05 | -0.05 |
| 2016-06-20 | Reiterated Rating | Leerink Swann | Buy | |
| 2016-06-08 | Reiterated Rating | Cantor Fitzgerald | Buy | |
| 2016-06-02 | Initiated Coverage | SunTrust | Buy | $7.00 |
| 2016-06-02 | Initiated Coverage | SunTrust Banks Inc. | Buy | $7.00 |
| 2016-05-19 | Reiterated Rating | Leerink Swann | Outperform | $6.00 |
| 2016-05-05 | Reiterated Rating | Leerink Swann | Buy | $6.00 |
| 2016-05-04 | Reiterated Rating | Cantor Fitzgerald | Buy | |
| 2016-05-04 | Reiterated Rating | Jefferies Group | Buy | |
| 2016-04-02 | Reiterated Rating | Piper Jaffray | Buy | |
| 2016-04-02 | Reiterated Rating | Piper Jaffray Cos. | Buy | |
| 2016-02-03 | Lower Price Target | Stifel Nicolaus | Buy | $8.00 to $7.00 |
| 2016-02-02 | Reiterated Rating | Cantor Fitzgerald | Buy | |
| 2015-12-17 | Reiterated Rating | Leerink Swann | Outperform | $9.00 to $6.00 |
| 2015-12-17 | Reiterated Rating | Cantor Fitzgerald | Buy | $13.00 |
| 2015-12-16 | Reiterated Rating | Piper Jaffray | Buy | |
| 2015-09-29 | Reiterated Rating | Piper Jaffray | Buy | |
| 2015-09-29 | Reiterated Rating | Cantor Fitzgerald | Buy | $13.00 |
| 2015-07-23 | Reiterated Rating | Cantor Fitzgerald | Buy | $13.00 |
| 2015-07-22 | Reiterated Rating | Piper Jaffray | Buy | |
| 2015-06-02 | Set Price Target | Piper Jaffray | Buy | $15.00 |
| 2015-02-18 | Boost Price Target | Piper Jaffray | Overweight | $9.00 to $15.00 |
| 2015-01-26 | Set Price Target | Cantor Fitzgerald | Buy | $13.00 |
| 2015-01-26 | Boost Price Target | JPMorgan Chase & Co. | Overweight | $8.00 to $9.00 |
| 2015-01-26 | Upgrade | Jefferies Group | Buy | $9.00 to $10.00 |
| 2015-01-26 | Boost Price Target | Stifel Nicolaus | Buy | $6.00 to $9.00 |
| 2014-12-05 | Boost Price Target | Jefferies Group | Buy | $7.00 to $9.00 |
| 2014-08-13 | Reiterated Rating | Leerink Swann | Outperform | $8.00 to $6.00 |
| 2014-05-29 | Initiated Coverage | Cantor Fitzgerald | Buy | $9.00 |
| 2013-11-01 | Boost Price Target | BMO Capital Markets | Market Perform | $3.00 to $4.00 |
| 2013-08-09 | Reiterated | Stifel | Buy | $7 to $8 |
| 2010-07-23 | Upgrade | UBS | Neutral to Buy | $4.25 |
| 2010-04-22 | Downgrade | UBS | Buy to Neutral | |
| 2009-11-05 | Upgrade | UBS | Neutral to Buy | |
| 2009-09-04 | Downgrade | Robert W. Baird | Outperform to Neutral | $10 to $3 |
| 2009-09-04 | Downgrade | Leerink Swann | Outperform to Mkt Perform | $6 to $2 |
| 2009-09-04 | Downgrade | Boenning & Scattergood | Outperform to Neutral | |
| 2009-06-17 | Initiated | Boenning & Scattergood | Outperform | $6 |
| 2008-05-07 | Reiterated | Rodman & Renshaw | Mkt Outperform | $18 to $15 |
| 2008-02-07 | Initiated | William Blair | Outperform | |
| 2007-12-20 | Reiterated | Collins Stewart | Buy | $17 to $16 |
| 2007-12-04 | Initiated | Morgan Joseph | Buy | $16 |
| 2007-11-07 | Reiterated | Collins Stewart | Buy | $20 to $17 |
| 2007-10-09 | Initiated | Lehman Brothers | Overweight | $16 |
| 2007-08-13 | Initiated | Rodman & Renshaw | Mkt Outperform | $18 |
| 2007-05-23 | Initiated | JP Morgan | Overweight | |
| 2007-01-04 | Reiterated | Piper Jaffray | Outperform | $14 to $20 |
| 2016-06-20 | Reiterated Rating | Leerink Swann | Buy | |
| 2016-06-08 | Reiterated Rating | Cantor Fitzgerald | Buy | |
| 2016-06-02 | Initiated Coverage | SunTrust | Buy | $7.00 |
| 2016-06-02 | Initiated Coverage | SunTrust Banks Inc. | Buy | $7.00 |
| 2016-05-19 | Reiterated Rating | Leerink Swann | Outperform | $6.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In ARRY 182 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| BlackRock Inc. | 15.87M |
| Vanguard Group, Inc | 13.35M |
| FMR LLC | 9.07M |
| BlackRock Fund Advisors | 7.48M |
| Invesco Ltd. | 6.23M |
| FRONTIER CAPITAL MANAGEMENT CO LLC | 5.31M |
| Electron Capital Partners, LLC | 5.10M |
| Blackstone Group L.P. | 5.04M |
| PICTET ASSET MANAGEMENT LTD | 4.98M |
| BlackRock Institutional Trust Company, N.A. | 4.47M |
| GRANAHAN INVESTMENT MANAGEMENT INC/MA | 3.94M |
| STATE STREET CORP | 3.81M |
| BNP Paribas Investment Partners S.A. | 3.11M |
| EverPoint Asset Management, LLC | 3.10M |
| ROBECOSAM AG | 3.03M |
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| Redmile Group, LLC | 15.20% (19150650) | ARRY / FOLD / |
| BVF PARTNERS L P/IL | 5.60% (7058997) | ARQL / ARRY / CAPS / CCXI / CNCE / CTIC / INFI / LGND / NBIX / ONTY / PTN / RGDO / RGEN / RIGL / TRGT / XENE / |
| ARRAY BIOPHARMA INC | 1.28% (1609560) | ARRY / LOXO / |
| KOCH KEVIN President, CSO | 0.62% (786917) | ARRY / SGNL / |
| CONWAY ROBERT CEO | 0.50% (633386) | ABIO / ARRY / |
| CARUTHERS MARVIN H | 0.21% (269040) | ARRY / |
| Squarer Ron CEO | 0.17% (211575) | ARRY / |
| Sandor Victor Chief Medical Officer. | 0.17% (210086) | ARRY / |
| Robbins Andrews R SVP, Commercial Operations | 0.13% (159467) | ARRY / |
| CARRUTHERS MICHAEL CFO | 0.09% (112265) | ARRY / |
| Saccomano Nicholas A CSO | 0.04% (55278) | ARRY / |
| MOORE JOHN R VP, General Counsel | 0.03% (40102) | ARRY / |
| Haddock Jason CFO | 0.02% (28868) | ARRY / |
| VAN LUNSEN GIL J | 0.02% (19297) | ARRY / MTSI / OKS / |
| LEFKOFF KYLE | 0.01% (17720) | ARRY / SGNL / |
| Fyfe Gwen A. | 0.01% (10000) | ARRY / INFI / ONTY / |
| BAUM CHARLES M | 0.01% (10000) | ARRY / MRTX / |
| Orwin John A | 0.01% (10000) | AFFY / ARRY / RLYP / SGEN / |
| SNITMAN DAVID COO and VP, Business Devel. | 0.01% (7477) | ARRY / |
UM